Details of the Drug

General Information of Drug (ID: DMG592Q)

• Drug Name: Solifenacin
• Synonyms: Vesicare; Vesikur; Solifenacin succinate; Solifenacin succinate [USAN]; YM 905; Solifenacin (INN); Solifenacin [INN:BAN]; Vesicare (TN); YM-53705; YM-67905; YM-905; Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1)

Indication

Disease Entry	ICD 11	Status	REF
Overactive bladder	GC50.0	Approved	[1]
Priapism	N.A.	Investigative	[2]

• Therapeutic Class: Antispasmodics
• Affected Organisms: Humans and other mammals
• ATC Code:
  G04BD08: Solifenacin
  G04BD: Drugs for urinary frequency and incontinence
  G04B: UROLOGICALS
  G04: UROLOGICALS
  G: GENITO URINARY SYSTEM AND SEX HORMONES
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 362.5
  Logarithm of the Partition Coefficient (xlogp); 4
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-1.5 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Bioavailability: The bioavailability of drug is 23% [3]
  Clearance: The renal clearance of drug is 0.67-1.51 L/h [5]
  Elimination: 69.2 +/- 7.8% of a radiolabelled dose is recovered in the urine, 22.5 +/- 3.3% was recovered in feces, and 0.4 +/- 7.8% was recovered in exhaled air [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 33 - 85 hours [5]
  Metabolism: The drug is metabolized via the cytochrome P450 [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.29728 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [7]
  Vd: The volume of distribution (Vd) of drug is 600 L [5]
• Chemical Identifiers:
  Formula: C23H26N2O2
  IUPAC Name: [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
  Canonical SMILES: C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5
  InChI: InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
  InChIKey: FBOUYBDGKBSUES-VXKWHMMOSA-N
• Cross-matching ID:
  PubChem CID: 154059
  ChEBI ID: CHEBI:135530
  CAS Number: 242478-37-1
  UNII: A8910SQJ1U
  DrugBank ID: DB01591
  TTD ID: D0L4YD
  INTEDE ID: DR1497
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M3 (CHRM3)	TTQ13Z5	ACM3_HUMAN	Antagonist	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[9]

Molecular Expression Atlas of This Drug

• The Studied Disease: Overactive bladder
• ICD Disease Classification: GC50.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Muscarinic acetylcholine receptor M3 (CHRM3)	DTT	CHRM3	4.61E-07	-0.59	-0.73
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Solifenacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[10]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Midostaurin.	Acute myeloid leukaemia [2A60]	[11]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Solifenacin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[12]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[13]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Solifenacin and Oliceridine.	Acute pain [MG31]	[14]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[15]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[15]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Ivabradine.	Angina pectoris [BA40]	[16]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Dronedarone.	Angina pectoris [BA40]	[11]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[17]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Levalbuterol.	Asthma [CA23]	[18]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Solifenacin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Solifenacin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Retigabine.	Behcet disease [4A62]	[11]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Cariprazine.	Bipolar disorder [6A60]	[21]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Solifenacin caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[12]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Eribulin.	Breast cancer [2C60-2C6Y]	[11]
Tucatinib	DMBESUA	Major	Decreased metabolism of Solifenacin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Solifenacin caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Solifenacin when combined with Acetylcholine.	Cataract [9B10]	[22]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[23]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[24]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[24]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Probucol.	Coronary atherosclerosis [BA80]	[11]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Pasireotide.	Cushing syndrome [5A70]	[11]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Osilodrostat.	Cushing syndrome [5A70]	[16]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Solifenacin caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[12]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Solifenacin caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[12]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Solifenacin and OPC-34712.	Depression [6A70-6A7Z]	[21]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Mepenzolate.	Digestive system disease [DE2Z]	[21]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[11]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Deutetrabenazine.	Dystonic disorder [8A02]	[26]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Ingrezza.	Dystonic disorder [8A02]	[27]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Solifenacin caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Solifenacin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Solifenacin caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[12]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Solifenacin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Telaprevir	DMMRV29	Major	Decreased metabolism of Solifenacin caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Solifenacin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Solifenacin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[11]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Solifenacin caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[12]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[21]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Solifenacin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[12]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Solifenacin caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[12]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Solifenacin and ITI-007.	Insomnia [7A00-7A0Z]	[21]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[16]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Phenolphthalein.	Irritable bowel syndrome [DD91]	[11]
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Solifenacin when combined with R0-93877.	Irritable bowel syndrome [DD91]	[30]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Crizotinib.	Lung cancer [2C25]	[31]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Solifenacin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[32]
Ceritinib	DMB920Z	Major	Decreased metabolism of Solifenacin caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Solifenacin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[12]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Osimertinib.	Lung cancer [2C25]	[33]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Selpercatinib.	Lung cancer [2C25]	[16]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Lumefantrine.	Malaria [1F40-1F45]	[20]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Hydroxychloroquine.	Malaria [1F40-1F45]	[34]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[16]
Idelalisib	DM602WT	Major	Decreased metabolism of Solifenacin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Solifenacin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[12]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Vemurafenib.	Melanoma [2C30]	[11]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and LGX818.	Melanoma [2C30]	[35]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Solifenacin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[12]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Solifenacin caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[36]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Panobinostat.	Multiple myeloma [2A83]	[37]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Siponimod.	Multiple sclerosis [8A40]	[20]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Fingolimod.	Multiple sclerosis [8A40]	[11]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Solifenacin and Ozanimod.	Multiple sclerosis [8A40]	[38]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Romidepsin.	Mycosis fungoides [2B01]	[11]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Solifenacin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[11]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Phenindamine.	Nasopharyngitis [CA00]	[21]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Lofexidine.	Opioid use disorder [6C43]	[11]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Rucaparib.	Ovarian cancer [2C73]	[11]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Triclabendazole.	Parasitic worm infestation [1F90]	[11]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Pimavanserin.	Parkinsonism [8A00]	[39]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Solifenacin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[40]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Methylscopolamine.	Peptic ulcer [DA61]	[21]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[41]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Lefamulin.	Pneumonia [CA40]	[42]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Solifenacin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[20]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Degarelix.	Prostate cancer [2C82]	[16]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and ABIRATERONE.	Prostate cancer [2C82]	[16]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Solifenacin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[12]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Relugolix.	Prostate cancer [2C82]	[16]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Iloperidone.	Schizophrenia [6A20]	[11]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Molindone.	Schizophrenia [6A20]	[21]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Thiothixene.	Schizophrenia [6A20]	[21]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Amisulpride.	Schizophrenia [6A20]	[43]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Asenapine.	Schizophrenia [6A20]	[11]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Solifenacin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[16]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Solifenacin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
Armodafinil	DMGB035	Minor	Increased metabolism of Solifenacin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[44]
LEE011	DMMX75K	Major	Decreased metabolism of Solifenacin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[11]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[11]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Solifenacin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[45]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Solifenacin caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[12]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Solifenacin and Lenvatinib.	Thyroid cancer [2D10]	[11]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Solifenacin and Cabozantinib.	Thyroid cancer [2D10]	[16]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Solifenacin caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[12]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Solifenacin and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[21]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7483).
• [2] Solifenacin FDA Label
• [3] Latini R, Tognoni G, Kates RE: Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984 Mar-Apr;9(2):136-56. doi: 10.2165/00003088-198409020-00002.
• [4] BDDCS applied to over 900 drugs
• [5] Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302. doi: 10.2165/00003088-200948050-00001.
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [8] Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
• [9] Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
• [10] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [11] Canadian Pharmacists Association.
• [12] Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
• [13] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [14] Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
• [15] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [16] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [17] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [18] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [19] Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
• [20] Cerner Multum, Inc. "Australian Product Information.".
• [21] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [22] Multum Information Services, Inc. Expert Review Panel.
• [23] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [24] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [25] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [26] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [27] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [28] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [29] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [30] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [31] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [32] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [33] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [34] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [35] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [36] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [37] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [38] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [39] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [40] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [41] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [42] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [43] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [44] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [45] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.